Vikram Purohit: Hi. Good afternoon. Thanks for taking our questions. So two from our side. First, would just love to get your thoughts on Sotyktu’s commercial performance to date and how it’s impacted if it has in your view of the commercial opportunity for a therapy like 958 in psoriasis? And then secondly, maybe a question for Marty. Could you just remind us what level of pipeline development is contemplated in your current cash guidance and runway, and how far the runway gets you for the current set of lead programs? Thanks.
Raju Mohan: So maybe Marty can take both questions and start with the commercial Sotyktu sort of thing and then go back to the second one.
Marty Auster: Well, it’s a rare treat to get both of them. Thanks, Vikram. So in terms of Sotyktu’s commercial performance, I think we’re quite encouraged by the early days of Sotyktu. Obviously, there is — Bristol has been providing quarterly updates about their commercial performance in this space. They’re getting substantial, significant market share relative to the other approved oral therapy on the market in psoriasis. They’re continuing to kind of see share coming from all different avenues, which is highly encouraging. That includes sort of treatment naive to systemic therapy patients in psoriasis, conversions from the other approved oral therapy Otezla, conversions from patients currently taking biologics who are seeking to get off of injectables and over to orals.
We think long term about the market opportunity here. This is a $25 billion global class of therapeutics. We think that oral agents overall are going to play a very significant and substantial meaningful portion of that market. Currently, the oral portion of that market is just about 10% or so. We think that’s going to grow meaningfully from here. We think TYK2 is going to be a major player within that class, obviously, with the introduction of Sotyktu and then obviously our own development in other TYK2 plans we think look attractive that are coming online in the next several years. So I think it all looks pretty favorable. Shifting over to the cash guidance question, Vikram. So our cash guidance is forecast to bring us into 2025. And what that includes then is sort of Phase 3 prep work and the ability for us to kind of be able to be on track for Phase 3 launches in 2024 for both VTX002 ulcerative colitis program as well as for VTX958 in psoriasis.
It includes completion of the VTX958 Phase 2 programs in Crohn’s disease as well as in psoriatic arthritis, both of which we’re expecting to report data in 2024. It includes completion of the Phase 1 SAD and MAD that Bill described earlier for VTX3232, our CNS directed NLRP3 inhibitor as well as our Phase 2 proof of mechanism trial in CAPS patients with 2735. It does not obviously then get us through completion of those Phase 3 trials for psoriasis or UC, but allows us to kind of be positioned to commence and allows us to complete all the other ongoing clinical work that’s happening now. If we continue to kind of advance, obviously we will have additional capital needs eventually.
Vikram Purohit: Understood. Thank you.
Operator: Thank you. Our next question will come from Yasmeen Rahimi with Piper Sandler.
Unidentified Analyst: Hi. This is [indiscernible] speaking in for Yasmeen Rahimi at Piper. Thank you for taking our questions. Our first question is, as we will be eager to do our comparisons of SERENITY to other oral psoriasis agents, which PASI score in your view is the most reflective of drug activity and dose ranging, and what type of activities have been completed in regards to Phase 3 prep costs VTX958 and VTX002? Thank you so much.
